Literature DB >> 24678008

Tumoral heterogeneity of hepatic cholangiocarcinomas revealed by MALDI imaging mass spectrometry.

Julie Le Faouder1, Samira Laouirem, Theodore Alexandrov, Soundes Ben-Harzallah, Thibaut Léger, Miguel Albuquerque, Pierre Bedossa, Valérie Paradis.   

Abstract

Cholangiocarcinoma (CC) is the second most common primary malignancy of the liver. Although all CC derive from biliary epithelial cells, two main subtypes, hilar (H), and peripheral (P) CC are described. The objective of the study was to compare, using MALDI imaging mass spectrometry (MALDI IMS), in situ proteomic profiles of H- and P-CC in order to assess whether these subtypes may express different markers and to describe their respective localizations. Twenty-seven CC (16 P-CC and 11 H-CC) were subjected to MALDI IMS. Proteomic data were submitted to a dedicated cross-classification comparative design, enabling comparison of the entire generated spectra. Immunohistochemistry was performed for validation. Comparative analysis yielded a list of 19 differential protein peaks for the two subtypes, 14 of which were overexpressed in H-CC and five in P-CC. Among H-CC protein markers, most discriminant were human neutrophil peptides 1-3 that were expressed mainly by tumor cells and S100 proteins (A6 and A11) that were restricted to the stromal area. In P-CC, thymosin β4 was diffusely overexpressed. These results highlight the potential of MALDI IMS to discover new relevant biomarkers of CC and to characterize the heterogeneity of the two different subtypes.
© 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  Biomarker; Biomedicine; Cholangiocarcinoma; MALDI imaging mass spectrometry

Mesh:

Substances:

Year:  2014        PMID: 24678008     DOI: 10.1002/pmic.201300463

Source DB:  PubMed          Journal:  Proteomics        ISSN: 1615-9853            Impact factor:   3.984


  7 in total

Review 1.  Evolution of the liver biopsy and its future.

Authors:  Dhanpat Jain; Richard Torres; Romulo Celli; Jeremy Koelmel; Georgia Charkoftaki; Vasilis Vasiliou
Journal:  Transl Gastroenterol Hepatol       Date:  2021-04-05

Review 2.  Emerging proteomic technologies for elucidating context-dependent cellular signaling events: A big challenge of tiny proportions.

Authors:  Sarah J Parker; Koen Raedschelders; Jennifer E Van Eyk
Journal:  Proteomics       Date:  2015-02-10       Impact factor: 3.984

3.  MALDI Mass Spectrometry Imaging for the Distinction of Adenocarcinomas of the Pancreas and Biliary Tree.

Authors:  Christine Bollwein; Juliana Pereira Lopes Gonҫalves; Kirsten Utpatel; Wilko Weichert; Kristina Schwamborn
Journal:  Molecules       Date:  2022-05-27       Impact factor: 4.927

4.  Spatial Tissue Proteomics Quantifies Inter- and Intratumor Heterogeneity in Hepatocellular Carcinoma (HCC).

Authors:  Katarzyna Buczak; Alessandro Ori; Joanna M Kirkpatrick; Kerstin Holzer; Daniel Dauch; Stephanie Roessler; Volker Endris; Felix Lasitschka; Luca Parca; Alexander Schmidt; Lars Zender; Peter Schirmacher; Jeroen Krijgsveld; Stephan Singer; Martin Beck
Journal:  Mol Cell Proteomics       Date:  2018-01-23       Impact factor: 5.911

Review 5.  Circulating Tumor Cells as a Tool for Assessing Tumor Heterogeneity.

Authors:  Marta Tellez-Gabriel; Marie-Françoise Heymann; Dominique Heymann
Journal:  Theranostics       Date:  2019-06-19       Impact factor: 11.556

6.  Mass spectrometry-based analysis of formalin-fixed, paraffin-embedded distal cholangiocarcinoma identifies stromal thrombospondin-2 as a potential prognostic marker.

Authors:  Johannes Byrling; Theresa Kristl; Dingyuan Hu; Indira Pla; Aniel Sanchez; Agata Sasor; Roland Andersson; György Marko-Varga; Bodil Andersson
Journal:  J Transl Med       Date:  2020-09-04       Impact factor: 5.531

7.  In situ Detecting Lipids as Potential Biomarkers for the Diagnosis and Prognosis of Intrahepatic Cholangiocarcinoma.

Authors:  Jiayi Li; Qiao Chen; Lei Guo; Ji Li; Bao Jin; Xiangan Wu; Yue Shi; Haifeng Xu; Yongchang Zheng; Yingyi Wang; Shunda Du; Zhili Li; Xin Lu; Xinting Sang; Yilei Mao
Journal:  Cancer Manag Res       Date:  2022-09-26       Impact factor: 3.602

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.